Loading...
XLONSTX
Market cap26mUSD
Dec 27, Last price  
2.70GBP
1D
-1.82%
1Q
-43.75%
IPO
-98.33%
Name

Shield Therapeutics PLC

Chart & Performance

D1W1MN
XLON:STX chart
P/E
—
P/S
161.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
43.23%
Rev. gr., 5y
1.95%
Revenues
13m
+192.93%
00304,000637,00011,881,000719,00010,387,0001,519,0004,467,00013,085,000
Net income
-33m
L-17.68%
-12,905,000-23,627,000-15,016,000-19,588,000-1,794,000-8,800,000-2,630,000-19,336,000-40,444,000-33,293,000
CFO
-30m
L+64.10%
-3,341,000-4,183,000-10,256,000-16,151,000-178,000-4,066,000-1,400,000-16,738,000-18,247,000-29,943,240
Earnings
Apr 28, 2025

Profile

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
URL
https://www.shieldtherapeutics.com/
IPO date
Feb 26, 2016
Employees
27
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
13,085
192.93%
4,467
194.08%
1,519
-85.38%
Cost of revenue
47,757
46,881
31,844
Unusual Expense (Income)
NOPBT
(34,672)
(42,414)
(30,325)
NOPBT Margin
Operating Taxes
918
362
(229)
Tax Rate
NOPAT
(35,590)
(42,776)
(30,096)
Net income
(33,293)
-17.68%
(40,444)
109.16%
(19,336)
635.21%
Dividends
Dividend yield
Proceeds from repurchase of equity
26,817
5
27,705
BB yield
-55.40%
-0.03%
-30.46%
Debt
Debt current
214
89
156
Long-term debt
20,440
6,097
156
Deferred revenue
Other long-term liabilities
Net debt
9,713
3,365
(11,805)
Cash flow
Cash from operating activities
(29,943)
(18,247)
(16,738)
CAPEX
(239)
(1,895)
(2,064)
Cash from investing activities
(2,430)
(1,695)
(2,051)
Cash from financing activities
49,656
7,707
27,584
FCF
(46,379)
(40,297)
(32,218)
Balance
Cash
10,941
2,821
12,117
Long term investments
Excess cash
10,287
2,598
12,041
Stockholders' equity
(144,121)
(139,194)
(101,908)
Invested Capital
182,360
150,494
143,048
ROIC
ROCE
EV
Common stock shares outstanding
722,544
233,190
204,410
Price
0.07
-4.96%
0.07
-84.16%
0.45
-29.92%
Market cap
48,410
194.47%
16,440
-81.93%
90,962
18.70%
EV
58,123
19,805
79,157
EBITDA
(33,601)
(40,052)
(28,118)
EV/EBITDA
Interest
1,016
389
8
Interest/NOPBT